Advertisement

Annals of Surgical Oncology

, Volume 26, Issue 5, pp 1236–1237 | Cite as

ASO Author Reflections: Oncotype DX RS Complementing the Prognostic Stage in the Updated AJCC 8th Edition for T1-2N1M0 ER-Positive HER2-Negative Breast Cancer

  • Maoli Wang
  • Kejin Wu
  • Hongliang ChenEmail author
ASO Author Reflections
  • 168 Downloads

Notes

Disclosure

Authors declare that he has no conflicts of interest.

References

  1. 1.
    Giuliano AE, Edge SB, Hortobagyi GN. Eighth edition of the AJCC cancer staging manual: breast cancer. Ann Surg Oncol. 2018;25:1783–5.CrossRefGoogle Scholar
  2. 2.
    Albain KS, Barlow WE, Shak S, et al. Prognostic and predictive value of the 21-gene recurrence score assay in postmenopausal women with node-positive, oestrogen-receptor-positive breast cancer on chemotherapy: a retrospective analysis of a randomised trial. Lancet Oncol. 2010;11:55–65.CrossRefGoogle Scholar
  3. 3.
    Dowsett M, Cuzick J, Wale C, et al. Prediction of risk of distant recurrence using the 21-gene recurrence score in node-negative and node-positive postmenopausal patients with breast cancer treated with anastrozole or tamoxifen: a TransATAC study. J Clin Oncol. 2010;28:1829–34.CrossRefGoogle Scholar
  4. 4.
    Gluz O, Nitz UA, Christgen M, et al. West German Study Group phase 3 plan B trial: first prospective outcome data for the 21-gene recurrence score assay and concordance of prognostic markers by central and local pathology assessment. J Clin Oncol. 2016;34:2341–9.CrossRefGoogle Scholar
  5. 5.
    Wang M, Wu K, Zhang P, et al. The prognostic significance of Oncotype DX recurrence score in T1-2N1M0 ER-positive HER2-negative breast cancer based on the prognostic stage in the updated AJCC 8th edition. Ann Surg Oncol. 2018.  https://doi.org/10.1245/s10434-018-7068-3.

Copyright information

© Society of Surgical Oncology 2019

Authors and Affiliations

  1. 1.Department of Breast SurgeryObstetrics and Gynecology Hospital of Fudan UniversityShanghaiChina

Personalised recommendations